Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14421616 | 0.84 | KMT2A (0.41) | METAP2NPC1RAB9A | |
| SCHEMBL17066287 | 0.84 | NPC1 (0.46) | ADORA2ANPC1RAB9A | |
| SCHEMBL17066286 | 0.82 | KIF11 (0.46) | ADORA2ANPC1RAB9A | |
| SCHEMBL2617474 | 0.82 | NPC1 (0.40) | METAP2ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL14531238 | 0.82 | ADORA3 (0.33) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL1690213 | 0.81 | ADORA1 (0.47) | MAP2K1ADORA3ADORA2AADORA1RAB9A | |
| SCHEMBL2104701 | 0.79 | ADORA3 (0.33) | ADORA3ADORA2AADORA1 | |
| SCHEMBL2104139 | 0.78 | ALDH1A1 (0.35) | ADORA3ADORA2AADORA1BRAF | |
| SCHEMBL2570966 | 0.76 | NPC1 (0.42) | BRAFNPC1RAB9A | |
| SCHEMBL1690338 | 0.76 | MAPK1 (0.45) | MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | METAP2 3706/4885MAP2K1 2270/4885ADORA3 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.